Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of…

Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS

Quantum Biopharma intends to ask the U.S. Food and Drug Administration (FDA) this year for permission to start a Phase 2 clinical trial testing Lucid-21-302, its novel therapy for promoting […] The post Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS appeared first on Multiple Sclerosis News Today.